medigraphic.com

2015, Number 1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2015; 16 (1)

Deep venous thrombosis in older adults with cancer

Bustillo SMJ, López GD, Feito CT, García SF, Álvarez LY

Language: Spanish
References: 31
Page: 9-20
PDF size: 127.38 Kb.


ABSTRACT

Introduction: the venous thromboembolic disease constitutes one of the most ancient complications of the patients with cancer.
Objective: to characterize the deep venous thrombosis in older adults with cancer.
Methods: a descriptive study is realized in 89 major adults with cancer and diagnosis of deep venous thrombosis attended in the Hospital "Arnaldo Milián Castro" in the period from april, 2010 until april, 2013. The following information was extracted from the case histories: age, sex, and type of cancer and primary location of the same one, location of the thrombosis, diagnosis, and moment of occurrences, complications and treatment.
Results: one found that 44.94 % of the cases had an age between 60 and 69 years, predominating over the masculine sex. The neoplasias of colon, prostate and lung were those of major presentation in the masculine sex and of colon and gynecological in the feminine sex. The moment of occurrence of the thrombosis was 47.19 % during the evolution of the illness and in 25.84 % post-chemotherapy. The most frequent location was the ileo-femoral. The diagnosis was realized clinically in 68.54 % of the cases. The heparin of low molecular weight and the Warfarine were the medicines used for the treatment in 44.94 % of the patients. Complications were not observed in most of the patients.
Conclusions: venous thromboembolism is one of the highest impact complications on patients with cancer, so it is necessary to carry out good prophylaxis and early adequate treatment.


REFERENCES

  1. Donati MB. Thrombosis and cancer: Trousseau syndrome revisited. Best Pract Res Clin Hematol. 2009;22:3-8.

  2. del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Hemost. 2007 [cited 2013 May 15];5(1):70-4. Available from: http//www.ncbi.nlm.nih.gov/pmc/pubmed/pmc17239164/

  3. Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78-82.

  4. Geerts WH, Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(Suppl 6):381S-453S.

  5. Ministerio de Salud Pública. Anuario estadístico de Cuba del 2009-2012. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2012 [citado 30 Oct 2013]. Disponible en: http://www.bvscuba.sld.cu/anuario-estadisticode- cuba/

  6. Lecumberri R, Feliu J, Rocha E. Tromboembolia venosa en pacientes con cáncer. Med Clin (Barc). 2006;127(1):22-32.

  7. Salama P. Trombosis y Cáncer. An Sist Sanit Navar. 2004;(Supl 3):45-51.

  8. Longevidad saludable y salud de los adultos mayores. 2010 [citado 18 Oct 2010]. Disponible en: http://www.salud.carso.org/tm inves longevidad.html

  9. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009;27(Suppl 1):63-74.

  10. Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009;123(Suppl 4):S18-21.

  11. Girre V, Braen E, Le Caer H, Ghesquieres H, Peyurat P, Terret C, et al. Clinical management of the most important cancers in older patients. Rev Prat. 2009;59(3):347-58.

  12. Khorana AA. Assessing risk of venous thromboembolism in the patient with cancer. Ann Oncol. 2009 [cited 2013 Sept 20];20(10). Available from: http://www.annonc.oxfordjournals.org/

  13. Haubold K, Rink M, Spath B. Tissue factor pro-coagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost. 2009 [cited 2012 Sept 15];101(6):1147-55. Available from: http//www.ncbi.nlm.nih.gov/pmc/pubmed/pmc19492160/

  14. Aleem A, Rahman AA, Alsaleh K. Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia. Asian Pacific J Cancer Prev. 2012 [cited 2012 Sept 15];13(8)1311-1. Available from: http://www.dx.doi.org/10.7314/APJCP.2012.13.4.1311

  15. Rickles FR. Cancer and thrombosis is a sticky Business. Blood. 2008;112:2594-5.

  16. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27:4889-94.

  17. França A, Reis A, Paulino A, Lohman C, Cartucho D, Campello G, et al. Venous thromboembolism risk factors and practices of prophylaxis: Endorse study results in Portugal. Acta Med Port. 2011;24:951-60.

  18. Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009;20:1619-30.

  19. Font C, Farru B, Vidal L. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol. 2011 [cited 2013 Sept 20];22(9). Available from: http://www.annonc.oxfordjournals.org/

  20. Khosravi Shahi P, Díaz Muñoz de la Espada VM. Adenocarcinoma de páncreas: actualizaciones terapéuticas. An Med Int. 2009;22(8):390-4.

  21. Leonard Pérez D. Diagnóstico clínico de la trombosis venosa profunda. Rev Cubana Angiol Cir Vasc. 2013 [citado 20 Sept 2013];14(supl). Disponible en: http://www.bvs.sld.cu/revistas/ang/vol14_sup_13/ang0313sup.htm

  22. Ameneiro Pérez S. Diagnóstico no invasivo de la trombosis venosa profunda. Rev Cubana Angiol Cir Vasc. 2013 [citado 20 Sept 2013];14(supl). Disponible en: http://www.bvs.sld.cu/revistas/ang/vol14_sup_13/ang0313sup.htm

  23. Perry JR, Rogers L, Laperriere N. Ontario Clinical Oncology Group; PRODIGE Investigators. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using Dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol. 2007;25(Suppl):2011-2.

  24. Klerk CPW, Smorenburg SM, Otten HM. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130-5.

  25. Kakkar AK, Levine MN, Kadziola Z. Low molecular weight heparin therapy with Dalteparin, and survival in advanced cancer: The Framing advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-8.

  26. Altinbas M, Coskun HS, Er O. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266-71.

  27. Lee AY, Rickles FR, Julian A. A randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123-9.

  28. Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program. 2010;20:144-9.

  29. Zwicker JI, Liebman HA, Bauer KA. Prediction and prevention of thromboembolic events with Enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: A randomized-controlled phase II trial (the Microtec study). Br J Hematol. 2013;160(4):530-7.

  30. Vemulapalli S, Chintala L, Tsimberidou AM. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a phase I clinic: the M. D. Anderson Cancer Center experience. Am J Hematol. 2009;84:408-13.

  31. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O´Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population based study. Arch Int Med. 1998;158:585-93.




2020     |     www.medigraphic.com